Climb Bio, Inc. financial data

Symbol
CLYM on Nasdaq
Industry
Pharmaceutical Preparations
Location
20 William Street, Suite 145, Wellesley Hills, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Eliem Therapeutics, Inc. (to 9/20/2024)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.57K % +42.7%
Debt-to-equity 2.03 % -39.1%
Return On Equity -38.9 % -23.8%
Return On Assets -38.2 % -25.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.5M shares +143%
Common Stock, Shares, Outstanding 67.3M shares +143%
Entity Public Float 196M USD +1384%
Common Stock, Value, Issued 7K USD +133%
Weighted Average Number of Shares Outstanding, Basic 48.2M shares +78.5%
Weighted Average Number of Shares Outstanding, Diluted 48.2M shares +78.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.2M USD -8.01%
General and Administrative Expense 16M USD -35.5%
Operating Income (Loss) -82M USD -104%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -73.9M USD -110%
Earnings Per Share, Basic -1.53 USD/shares -17.7%
Earnings Per Share, Diluted -1.53 USD/shares -17.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 87.2M USD -6.32%
Marketable Securities, Current 63.7M USD +365%
Assets, Current 155M USD +40.5%
Operating Lease, Right-of-Use Asset 490K USD +146%
Other Assets, Noncurrent 215K USD +1333%
Assets 217M USD +96.6%
Accounts Payable, Current 705K USD +968%
Accrued Liabilities, Current 4.07M USD +67.2%
Liabilities, Current 4.93M USD +74.1%
Operating Lease, Liability, Noncurrent 375K USD +2400%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 5.31M USD +84.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD
Retained Earnings (Accumulated Deficit) -230M USD -47.4%
Stockholders' Equity Attributable to Parent 212M USD +96.9%
Liabilities and Equity 217M USD +96.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.82M USD +88%
Net Cash Provided by (Used in) Financing Activities 15K USD -98.5%
Net Cash Provided by (Used in) Investing Activities 13.8M USD +137%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 67.3M shares +143%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 87.2M USD -6.32%
Deferred Tax Assets, Valuation Allowance 28.5M USD +36.6%
Deferred Tax Assets, Gross 28.6M USD +37.2%
Operating Lease, Liability 585K USD -15.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -73.9M USD -113%
Lessee, Operating Lease, Liability, to be Paid 611K USD -17.8%
Operating Lease, Liability, Current 157K USD -53%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15K USD -95.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 342K USD +45.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +13.3%
Deferred Tax Assets, Operating Loss Carryforwards 22.7M USD +32.6%
Share-based Payment Arrangement, Expense 5.56M USD -56.6%